Why Hepatitis C Screening Became a One-Time Test for Nearly All Adults

For years, routine U.S. hepatitis C screening focused on adults born from 1945 through 1965, because that birth cohort carried a large share of infections, and asking about stigmatized risks missed people. By 2020, the epidemiology and the treatment landscape supported a broader rule.

The U.S. Preventive Services Task Force now recommends screening asymptomatic adults ages 18 to 79 and gives the service a B grade. CDC recommends at least one lifetime screen for all adults 18 and older, with a narrow exception for settings that have documented hepatitis C RNA prevalence below 0.1%. CDC also recommends screening during every pregnancy and periodic testing while certain risks continue.

"One time" describes the default if you have no continuing risk. It does not mean one laboratory result answers every question forever. Hepatitis C testing has a sequence: an antibody test identifies immune recognition, and an RNA test determines whether virus is currently present.

Why the birth-cohort strategy made sense#

Older screening policy targeted people born from 1945 through 1965 because they had much higher hepatitis C prevalence than other age groups. Many infections arose decades earlier from blood transfusion before effective donor screening, medical practices before modern infection control, or injection drug use, and chronic infection could remain unnoticed while slowly damaging the liver.

A birth year was easier to implement than a detailed behavioral questionnaire, and it reduced dependence on disclosure and recognized that many people did not remember or know how infection occurred. Health systems could create an electronic reminder from information already in the chart.

The strategy found disease, but it left gaps. People outside the cohort still acquired hepatitis C. Some eligible adults were never offered a test. A birth-year alert also became less useful as the epidemic changed.

What changed in the epidemiology#

Hepatitis C is transmitted primarily through blood. In the 2010s, acute infections rose among younger adults in association with injection drug use and the broader opioid crisis, and a policy focused on one older cohort increasingly failed to include newly affected communities.

Risk-based testing remained essential, but it was not enough. People may not consider a past event relevant, may not be asked, or may avoid disclosing a stigmatized behavior. Clinicians may make inaccurate assumptions about who is at risk. A universal age-based offer reduces the number of personal judgments required before testing. CDC's evidence review found that a universal adult strategy was reasonable even at very low prevalence, and its recommendation includes an exception when a setting has documented current-infection prevalence below 0.1%, though CDC notes that few settings have established prevalence below that level.

Treatment changed the value of screening#

Screening is valuable when finding a condition leads to an intervention that improves outcomes. Older interferon-based treatment was prolonged, difficult to tolerate, and not reliably curative for everyone. Modern direct-acting antiviral therapy cures more than 95% of treated adults in the evidence reviewed by USPSTF, with shorter courses and fewer serious harms than older treatment.

Achieving sustained virologic response is associated with lower risks of liver-related death, cirrhosis, and liver cancer. Treatment also removes a source of onward transmission. These links form an indirect chain of evidence: accurate screening finds infection, RNA confirms it, effective treatment clears virus, and clearance is associated with better outcomes. The chain is only as strong as linkage to care, so a screening program that reports a reactive antibody but never obtains RNA, stages liver disease, or arranges treatment has not delivered the benefit it was designed for.

The first test looks for antibody#

Routine screening begins with an FDA-approved test for antibody to hepatitis C virus; antibody indicates that the immune system has encountered the virus, usually becoming detectable weeks after infection and generally remaining detectable for life.

A nonreactive antibody result usually means there is no evidence of prior infection, though it can be falsely nonreactive early after infection, in some people with severe immune compromise, or because of specimen or testing problems. When recent infection is plausible, RNA testing may be appropriate even with a nonreactive antibody.

A reactive antibody result has three main possibilities: current infection, past infection that cleared without treatment, or past infection that was cured; a false-reactive screen can also occur, especially in a low-prevalence population. Antibody alone cannot distinguish these states.

RNA answers whether infection is current#

HCV RNA testing detects viral genetic material in blood. A reactive antibody followed by detected RNA establishes current infection. A reactive antibody with RNA not detected usually means no current infection, commonly because of spontaneous clearance or successful treatment.

CDC recommends collecting the needed samples in one visit and using automatic reflex RNA testing after a reactive antibody result whenever possible, and that design keeps you from being lost between two appointments and turns the order into a complete current-infection assessment.

An isolated antibody result should not be presented as "you have hepatitis C" without explaining the need for RNA. A preliminary label can cause fear and stigma, and clear communication tells you what the first result means, what it does not mean, and when the final one will be ready.

Why one-time does not mean one test forever#

One-time screening is the default for adults without continuing risk and with no reason to suspect recent infection. CDC recommends routine periodic testing for people who currently inject drugs and share injection equipment and for people receiving maintenance hemodialysis. Other current risks can also justify repeat testing based on clinical judgment and guidance.

The exact interval depends on the setting and risk. USPSTF found limited evidence for one optimal frequency. The decision should consider continuing blood contact, local epidemiology, prevention options, and whether testing can be linked promptly to care.

Anyone who requests a hepatitis C test should be tested, according to CDC, because a person may reasonably prefer not to disclose a stigmatized risk. Universal screening should reduce stigma, not create a new interrogation before access.

Pregnancy is a separate recurring screen#

CDC recommends hepatitis C screening during every pregnancy, except in the rare setting with documented RNA prevalence below 0.1%. USPSTF's age-based recommendation also includes pregnant adults ages 18 to 79.

Each pregnancy is a new clinical interval, and infection can be acquired between pregnancies. Identifying infection supports maternal evaluation and a plan to test the infant. If risk continues during pregnancy, repeat testing later in pregnancy may be appropriate.

The test itself is a blood test. Treatment timing during pregnancy and infant follow-up require current specialist guidance. A prior negative result from another pregnancy does not replace the current recommendation.

After cure, antibody is not a reinfection test#

Successful treatment does not usually make the antibody test negative. You can also acquire hepatitis C again, because prior infection does not create reliable protective immunity. There is no hepatitis C vaccine.

If you have a prior reactive antibody and either cleared the infection or were cured, future assessment for reinfection uses HCV RNA, and repeating antibody only will likely reproduce the known reactive result and cannot show whether virus has returned. That distinction belongs in the record, because otherwise repeated antibody testing can create confusion, delayed RNA testing, or the mistaken belief that treatment failed.

A detected RNA result begins another pathway#

Current infection should lead to confirmation and clinical evaluation, not blame. The next assessment commonly includes liver enzymes, blood count, kidney function, medication review, hepatitis B and HIV status, fibrosis evaluation, and discussion of treatment. Vaccination against hepatitis A and B may be relevant when immunity is absent.

Medication interactions and comorbid liver or kidney disease influence treatment selection. People with cirrhosis need additional management and may require ongoing liver-cancer surveillance even after cure. The treatment pathway is highly effective but still needs appropriate prescribing and follow-up.

Partners and household members need accurate transmission information. Hepatitis C is not spread through hugging, sharing utensils, coughing, food, or ordinary contact. Avoiding shared items that may contain blood and using appropriate prevention for blood contact are more relevant than social isolation.

Universal screening still requires consent and trust#

Routine does not mean compulsory. USPSTF emphasizes that screening is voluntary, happens with your knowledge, and includes a chance for you to ask questions or decline. An opt-out workflow can normalize the service while preserving choice.

Neutral language matters. "We offer this to adults because infection often has no symptoms" is more accurate than implying a suspected behavior. Privacy, readable result explanations, and a reliable follow-up route help prevent a universal policy from reproducing stigma.

Cost and access also matter. Coverage for a screen does not guarantee affordable confirmatory testing or treatment. Programs should track the proportion of reactive antibody tests that receive RNA, the proportion of RNA-positive people linked to care, treatment initiation, and cure rather than celebrating screening volume alone.

What a negative result can and cannot say#

A negative antibody result is reassuring when enough time has passed and the immune response is expected to be intact. It does not rule out infection acquired very recently. CDC recommends RNA testing when infection within the prior six months is suspected, regardless of antibody result.

Testing windows should be discussed after a recent blood contact. The timing and type of contact, symptoms, immune status, and whether post-contact occupational protocols apply influence the plan. A later repeat test may be needed. A negative result also does not prevent future infection; prevention includes not sharing injection equipment or personal items that may contain blood, safe health-care practices, and access to substance-use treatment and harm-reduction services when relevant.

Safety boundaries#

Most chronic hepatitis C is asymptomatic. Jaundice, dark urine, pale stools, severe abdominal swelling, vomiting blood, black stools, confusion, easy bleeding, or marked sleepiness can signal significant liver disease and require prompt or emergency assessment.

A reactive screening result is not itself an emergency, but it deserves timely RNA completion. Do not delay evaluation because you feel well, and do not start supplements marketed as liver cleanses. Some supplements can injure the liver or interact with treatment.

The policy shift succeeded conceptually because it simplified the first decision: offer the test broadly. The clinical work begins with completing the sequence and connecting a confirmed infection to cure.